Filtered By:
Drug: Jardiance
Nutrition: Sodium

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 649 results found since Jan 2013.

Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors.
CONCLUSIONS: SGLT2i are usually safe and provide multiple benefits for patients with T2DM. However, during particular medical circumstances, and in association with usual co-medications, particularly if baseline glomerular filtration rate is decreased, patients treated with SGLT2i may be at risk of AKI, thus warranting caution when prescribed. PMID: 30084579 [PubMed - in process]
Source: The Israel Medical Association Journal - August 8, 2018 Category: General Medicine Tags: Isr Med Assoc J Source Type: research

Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center
In conclusion, prescription of evidence-based therapies to improve CVD outcomes in high-risk patients with T2DM remains very low after several years of evidence generation. Low uptake was evident across insurance types. Modest increases in use were observed after regulatory expansions in labeling; however, cardiologists rarely engaged in prescription, underscoring the need for widespread implementation strategies across health care systems.
Source: Journal of Cardiovascular Pharmacology - September 1, 2020 Category: Cardiology Tags: Original Article Source Type: research

Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
Authors: Shinozaki S, Tahara T, Lefor AK, Ogura M Abstract The long-term outcomes of patients with non-alcoholic fatty liver disease (NAFLD) treated with sodium-glucose cotransporter-2 inhibitors remain indeterminate. Empagliflozin improves hyperglycemia by increasing glucose excretion in the urine, and it reduces fat volume and insulin resistance. The aim of this study is to assess the effect of long-term empagliflozin therapy on hepatic inflammation, function and fibrosis in patients with NAFLD. This is a two-center retrospective observational study including patients with NAFLD complicated by type 2 diabetes mel...
Source: Journal of Medical Investigation - November 6, 2020 Category: General Medicine Tags: J Med Invest Source Type: research

Empagliflozin Eyed for Outpatient Chronic Hyponatremia Empagliflozin Eyed for Outpatient Chronic Hyponatremia
The SGLT2 inhibitor increased sodium and reduced neurocognitive dysfunction in patients with chronic hyponatremia due to the syndrome of inappropriate antidiuresis.Medscape Medical News
Source: Medscape Medical News Headlines - June 21, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news

Guideline-Directed Medical Therapies for Heart Failure with a Reduced Ejection Fraction in Older Adults: A Narrative Review on Efficacy, Safety and Timeliness
In conclusion, older adults suffering from heart failure with a reduced ejection fraction should not be denied treatment based on their age.
Source: Drugs and Aging - July 14, 2023 Category: Geriatrics Source Type: research

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
Conclusion: Incretins [dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA)] and sodium-glucose linked transporter-2 inhibitors (SGLT-2i) therapy steadily decreases the HbA1c level, and risk of developing diabetic incidents is reduced to between 333 and 465 cases among 6122 treated patients. Avoided cost for therapy of diabetes incidents account for between 305 and 510 thousand BGN. Introduction Incretin (DPP-4i and GLP-1 RA) and SGLT-2i groups are now routinely used for type 2 diabetes therapy and comprise a large number of medicinal products (Cheung et al., 2009; Lov...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring
CONCLUSIONS: Empagliflozin ranked the highest compared to the other SGLT-2is in the overall population and the trials including type 2 diabetes (T2D) patients with ASCVD or MRF at baseline, while dapagliflozin ranked the highest in the trials of patients with HF at baseline.SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022381556, identifier CRD42022381556.PMID:37469980 | PMC:PMC10353048 | DOI:10.3389/fendo.2023.1168755
Source: Atherosclerosis - July 20, 2023 Category: Cardiology Authors: Samit Ghosal Binayak Sinha Source Type: research

Benefits of SGLT2 Inhibitors beyond glycemic control - A focus on metabolic, cardiovascular, and renal outcomes.
CONCLUSIONS: SGLT2 inhibitors demonstrate some positive metabolic effects. In addition, empagliflozin specifically has demonstrated reduction in cardiovascular events and delay in the progression of kidney disease in patients with T2DM and a history of cardiovascular disease. Further data is needed to assess if this is a class effect. PMID: 28814245 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - August 16, 2017 Category: Endocrinology Authors: Minze MG, Will K, Terrell BT, Black RL, Irons BK Tags: Curr Diabetes Rev Source Type: research

Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
CONCLUSIONS: In patients with T2DM and CKD, SGLT2 inhibitors have a decreased glucose-lowering effect compared to patients without CKD. Renal benefits among patients with CKD are similar to those without CKD and include a significant reduction in albuminuria and reduced incidence of worsening albuminuria. Given that CKD and T2DM are both associated with increased cardiovascular risk, we believe these agents should considered as preferred add-on agents in most patients with uncontrolled T2DM and eGFR >30 ml/min/1.73m2. Ongoing studies will provide additional information as to whether these agents should be added to the c...
Source: Postgraduate Medicine - November 20, 2018 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function
CONCLUSIONS: Treatment with SGLT2 inhibitors can significantly improve LV function in patients with or without diabetes (especially those with HF or undergoing empagliflozin treatment).PMID:34791312 | DOI:10.1210/clinem/dgab834
Source: The Journal of Clinical Endocrinology and Metabolism - November 18, 2021 Category: Endocrinology Authors: Fang-Hong Shi Hao Li Long Shen Li Xu Heng Ge Zhi-Chun Gu Hou-Wen Lin Jun Pu Source Type: research